Itacitinib
Graft-versus-host disease (GVHD) and related hematologic malignancies
- CAS No.
- 1334298-90-6
- Indication Class
- Oncology / Hematology
- Patent Expiry
- To be assessed
- Therapeutic Area
- Hematology / Transplant
- Target / Mechanism
- JAK1
- Labeled Purity
- 98%+
- Registration Readiness
- GMP/DMF
- Commercialization Tier
- API (Commercialized)
- Linked Intermediates
- Confirm per inquiry
Key Intermediates for This API
Order: listed intermediates that accept enquiries first; fragments shared across several APIs rank higherNo intermediate entries are on file for this API yet. You can still enquire by CAS number — we will route it to the supply side for manual sourcing.
Listing Logic · Why It's Worth Listing
Addresses high-unmet need in post-transplant GVHD with a clear mechanism and limited competition, well suited to registration partnerships with transplant centers.
Hematology / Transplant · Marketed; available for immediate sourcing
GMP/DMF-ready; supports regulatory filing and audit in target markets
Intermediates confirmed per inquiry
Product Description
Itacitinib is an investigational oral drug that selectively inhibits the Janus kinase 1 (JAK1) enzyme. It is being evaluated in clinical trials for its potential to treat various solid tumors and hematologic malignancies by targeting pathways that drive tumor growth and inflammation.
Supply source: Unibest · Itacitinib, sourced, vetted and delivered by Unibest. Therapeutic area, indication and listing rationale are qualitative summaries based on public drug knowledge for business reference; actual registration availability and quality specifications are subject to DMF/GMP documentation and the technical agreement confirmed at order.